Sysmex (OTCMKTS:SSMXY) Trading Down 11.4% – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXYGet Free Report) was down 11.4% during mid-day trading on Tuesday . The company traded as low as $8.35 and last traded at $8.35. Approximately 6,967 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 270,783 shares. The stock had previously closed at $9.42.

Sysmex Price Performance

The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34. The firm has a fifty day simple moving average of $9.67 and a 200 day simple moving average of $11.12. The company has a market capitalization of $5.34 billion, a PE ratio of 17.69 and a beta of 1.14.

Sysmex (OTCMKTS:SSMXYGet Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The business had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a return on equity of 9.32% and a net margin of 8.86%. Equities analysts anticipate that Sysmex Corporation ADR will post 0.57 EPS for the current year.

About Sysmex

(Get Free Report)

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.

See Also

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.